| |
Survivors
|
Non-survivors
|
p-value
|
|---|
|
Patients
|
71
|
138
| |
|
Age, years
|
69.3 ± 10.2
|
73.8 ± 8.8
|
0.002
|
|
Male
|
56 (78.9)
|
116 (84.1)
|
0.352
|
|
BMI, kg/m2
|
22.2 ± 3.9
|
22.3 ± 3.8
|
0.795
|
|
Brinkman Index
| | | |
|
0/1–800/>800
|
26/14/25
|
42/31/46
|
0.719
|
|
F, H-J Classification scale
| | | |
|
1/2/3/4/5
|
1/3/3/16/42
|
1/1/4/12/83
|
0.012
|
|
Specialty hospital care
|
60 (84.5)
|
113 (81.9)
|
0.634
|
|
Ambulance transfer
|
32 (45.1)
|
69 (50.0)
|
0.499
|
|
Performing bronchoscopy
|
14 (19.7)
|
6 (4.4)
|
<0.001
|
|
Treatment regimen use
| | | |
|
Sivelestat
|
37 (52.1)
|
67 (48.9)
|
0.626
|
|
Diuretic drug
|
37 (52.1)
|
65 (47.1)
|
0.492
|
|
Anticoagulant therapy
|
37 (52.1)
|
50 (36.2)
|
0.027
|
|
Immunosuppressive therapy
|
30 (42.3)
|
45 (32.6)
|
0.169
|
|
Intravenous high-dose cyclophosphamide
|
9 (12.7)
|
23 (16.7)
|
0.448
|
|
PMX
|
4 (5.6)
|
9 (6.5)
|
0.801
|
|
Recombinant human soluble thrombomodulin
|
3 (4.2)
|
6 (4.4)
|
0.967
|
|
Antibiotic therapy
|
71 (100)
|
135 (97.8)
|
0.211
|
|
β-Lactams
|
60 (84.5)
|
116 (84.1)
|
0.933
|
|
Co-trimoxazole
|
56 (78.9)
|
59 (42.8)
|
<0.001
|
|
Quinolones
|
38 (53.5)
|
65 (47.1)
|
0.379
|
|
Macrolides
|
23 (32.4)
|
25 (18.1)
|
0.020
|
|
Tetracycline
|
6 (8.5)
|
12 (8.7)
|
0.952
|
|
Anti-MRSA antibiotics
|
6 (8.5)
|
11 (7.8)
|
0.904
|
|
Clindamycin
|
3 (4.2)
|
2 (1.5)
|
0.214
|
|
Aminoglycoside
|
2 (2.8)
|
1 (0.7)
|
0.228
|
|
Others
|
5 (7.0)
|
7 (5.1)
|
0.562
|
- Data are presented as mean ± SD or n (%), unless otherwise indicated. Definition of abbreviations: BMI = Body Mass Index, F, H-J = Fletcher, Hugh-Jones, PMX = Direct hemoperfusion with polymyxin B-immobilized fiber, MRSA = Methicillin-resistant Staphylococcus aureus. The total dose was not equal to 209 because there were missing values in the data file
